Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
…
0,700€
1,01%
Echtzeit-Aktienkurs Co-Diagnostics Inc.
Bid:
Ask:
Nachrichten zur Co-Diagnostics Inc. Aktie
Global Nanofiber Materials For Biomedical Market Size To worth USD 18184.90 Million By 2033 | CAGR of 24.80%
The Global Nanofiber Materials For Biomedical Market Size was Valued at USD 1984.90 Million in 2023 and the Worldwide Nanofiber…
Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript
…
Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript
…
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
…
Co-Diagnostics applies for FDA okay of COVID-19 test, stock rallies 17%
…
Plasmonic Materials Market Q4 2023 Exclusive Report with Accurate Forecast to 2031
Companies covered in this report are Nanopartz Inc., Nanocomposix Inc., Plasmonic Biosensors Inc., Nanospectra Biosciences Inc., Nanostructured and Amorphous Materials…
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
…
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do…
Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results
Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new…
Form 8-K Co-Diagnostics, Inc. For: Aug 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
SALT LAKE CITY, July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented…
Form 8-K Co-Diagnostics, Inc. For: May 12
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Co-Diagnostics, Inc. For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results
Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy SALT…
Co-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast
SALT LAKE CITY, May 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented…
Form 8-K Co-Diagnostics, Inc. For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Financial Officer kauft Aktien von Co-Diagnostics im Wert von 5.697$
Brown, Brian Lee - Vorstand - Tag der Transaktion: 2023-03-20...…
Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England
SALT LAKE CITY, March 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company…
Co-Diagnostics hits 52-week low as H.C. Wainwright cuts rating
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K Co-Diagnostics, Inc. For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Co-Diagnostics FY 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY, March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented…
Co-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform
SALT LAKE CITY, Feb. 22, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company…
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Co-Diagnostics, Inc.
Wilmington, Delaware--(Newsfile Corp. - February 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors…
Co-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design
Designed using the Companys proprietary platform, initial test design remains effective detection tool even after three years of variants and…
Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company…